Core Viewpoint - BioArctic AB's partner Eisai has achieved the first sales milestone for Leqembi, with sales reaching €200 million in Eisai's fiscal year 2024, resulting in a €10 million payment to BioArctic [1]. Company Overview - BioArctic AB is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including Alzheimer's disease [9]. - The company developed Leqembi (lecanemab), the first drug proven to slow the progression of early Alzheimer's disease [9]. - BioArctic has a collaboration with Eisai that began in 2005, which includes agreements for the development and commercialization of lecanemab [7]. Product Information - Leqembi is a humanized IgG1 monoclonal antibody targeting amyloid-beta aggregates, approved in multiple countries for treating mild cognitive impairment and mild Alzheimer's dementia [3][4]. - A supplemental Biologics License Application for less frequent intravenous maintenance dosing was approved by the FDA in January 2025 [5]. - Eisai's ongoing Phase 3 clinical study (AHEAD 3-45) is investigating lecanemab in individuals with preclinical Alzheimer's disease [6]. Financial Milestones - The sales milestone of €200 million entitles BioArctic to a €10 million payment, highlighting the financial success of Leqembi [1][8]. - BioArctic is entitled to payments related to regulatory approvals, sales milestones, and royalties on global sales of lecanemab [8].

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit following the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which led to a significant drop in its stock price [2]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders who purchased BioAge stock during the class period related to its IPO on September 26, 2024 [1]. - The complaint alleges that BioAge's announcement on December 6, 2024, regarding the discontinuation of the azelaprag trial was unexpected, as the company had previously promoted the drug's potential [2]. - Following the announcement, BioAge's stock price plummeted from $20.09 per share to $4.65 per share within a day [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 10, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [4]. - The firm aims to recover losses for investors caused by misleading statements or omissions that inflated stock prices [4].

LOS ANGELES, Feb. 12, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA).IF YOU SUFFERED A LOSS ON YOUR BIOAGE INVESTMENTS, CLICK HERE BEFORE MARCH 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About? The complaint filed alleges that, between pursuant and/or traceable to the Registrat ...

RADNOR, Pa., Feb. 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against BioAge Labs, Inc. (“BioAge”) (NASDAQ: BIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). T ...

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=127845&from=4CLASS PERIOD: This lawsuit is on ...

SAN DIEGO, Feb. 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant and/or traceable to BioAge Labs' registration statement issued in connection with BioAge Labs' initial public offering ("IPO") held on September 26, 2024, have until Monday, March 10, 2025 to seek appointment as lead plaintiff of the BioAge Labs class action lawsuit.  Captioned Soto v. BioAge Labs, Inc., No. 25-cv-00196 (N.D. Cal.), the BioAge La ...

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Investors have until March 10, 2025, to ask the Court to be appointed to lead the case ...

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=127272&from=4 CLASS PERIOD: This lawsuit is on ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether BioAge and certain of its officers an ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=126276&from=4CLASS PERIOD: This lawsuit is on b ...